Itraconazole

Blastomycosis, Paracoccidioidomycosis, Chromoblastomycosis + 15 more
Treatment
8 FDA approvals
20 Active Studies for Itraconazole

What is Itraconazole

ItraconazoleThe Generic name of this drug
Treatment SummaryItraconazole is an antifungal medication used to treat a variety of fungal infections including histoplasmosis, blastomycosis, cryptococcal meningitis, and aspergillosis. It works by blocking the production of a specific enzyme that is needed for the fungus to make its cell wall.
Sporanoxis the brand name
image of different drug pills on a surface
Itraconazole Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sporanox
Itraconazole
1992
35

Approved as Treatment by the FDA

Itraconazole, otherwise known as Sporanox, is approved by the FDA for 8 uses which include Fungal skin infection and Sporotrichosis .
Fungal skin infection
Sporotrichosis
Sporotrichosis
Cellulitis
Esophageal Candidiasis
Oropharyngeal Candidiasis
Chromoblastomycosis
Paracoccidioidomycosis

Effectiveness

How Itraconazole Affects PatientsItraconazole is a medicine used to treat fungal infections. It works by blocking an enzyme (cytochrome P450 14α-demethylase) found in fungi that is needed for the fungi to grow. This medicine has been shown to be effective at stopping the growth of various types of fungi, such as Cryptococcus neoformans and Candida spp. It can also be used to treat fungal infections in both healthy and immunocompromised (low immunity) animals.
How Itraconazole works in the bodyItraconazole stops the fungus from making a compound called ergosterol, which is vital for its cell membrane. When the cell membrane is weakened, it can no longer contain the contents of the cell, which will eventually lead to the death of the fungus. Itraconazole may also stop the fungus from getting energy, stop it from changing from a yeast form to a mycelial form, and prevent it from taking in nutrients.

When to interrupt dosage

The prescribed dosage of Itraconazole is contingent upon the diagnosed condition, including Onychomycosis, prophylaxis of Penicilliosis and Coccidioidal meningitis. The amount of dosage is contingent upon the technique of delivery, as detailed in the table below.
Condition
Dosage
Administration
Blastomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Paracoccidioidomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Chromoblastomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Onychomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Sporotrichosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Histoplasmosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Cellulitis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Coccidioidomycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
disseminated Other specified protozoal diseases
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
prophylaxis of Histoplasmosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
prophylaxis of Penicilliosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Aspergillosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Candidiasis, Vulvovaginal
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
talaromycosis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Coccidioides
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
HIV
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Oropharyngeal Candidiasis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous
Esophageal Candidiasis
, 100.0 mg, 200.0 mg, 10.0 mg/mL, 65.0 mg, 0.01 mg/mg, 0.05 mg/mg
Oral, , Capsule, Capsule - Oral, Tablet - Oral, Tablet, Solution - Oral, Solution, Capsule, coated pellets - Oral, Capsule, coated pellets, Kit, Cream - Topical, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Topical, Solution - Topical, Cream, Intravenous, Kit - Intravenous

Warnings

Itraconazole Contraindications
Condition
Risk Level
Notes
Congestive Heart Failure
Do Not Combine
Congestive heart failure
Do Not Combine
Cytochrome P450
Do Not Combine
suspected pregnancy
Do Not Combine
There are 20 known major drug interactions with Itraconazole.
Common Itraconazole Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Itraconazole.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Itraconazole.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Itraconazole.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Itraconazole.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Itraconazole.
Itraconazole Toxicity & Overdose RiskTests on mice, rats, and dogs have shown that itraconazole is not lethal when taken orally at doses of 320 mg/kg for mice and rats, or 200 mg/kg for dogs.
image of a doctor in a lab doing drug, clinical research

Itraconazole Novel Uses: Which Conditions Have a Clinical Trial Featuring Itraconazole?

137 active clinical trials are currently examining the potential of Itraconazole to ameliorate Chromomycosis, Dermatomycoses and Sporotrichosis.
Condition
Clinical Trials
Trial Phases
prophylaxis of Histoplasmosis
0 Actively Recruiting
Cellulitis
0 Actively Recruiting
Sporotrichosis
0 Actively Recruiting
Onychomycosis
0 Actively Recruiting
disseminated Other specified protozoal diseases
0 Actively Recruiting
Histoplasmosis
0 Actively Recruiting
Chromoblastomycosis
0 Actively Recruiting
Paracoccidioidomycosis
0 Actively Recruiting
Coccidioidomycosis
0 Actively Recruiting
prophylaxis of Penicilliosis
0 Actively Recruiting
Candidiasis, Vulvovaginal
2 Actively Recruiting
Not Applicable, Phase 3
Coccidioides
0 Actively Recruiting
Aspergillosis
0 Actively Recruiting
Esophageal Candidiasis
0 Actively Recruiting
talaromycosis
0 Actively Recruiting
Oropharyngeal Candidiasis
0 Actively Recruiting
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Blastomycosis
0 Actively Recruiting

Itraconazole Reviews: What are patients saying about Itraconazole?

5Patient Review
1/30/2017
Itraconazole for Fungal Disease of the Nails
I've been taking this medication for the past three months with absolutely no side effects that I can tell. No hair loss, no new nail growth... nothing. Maybe it's too early to say? Or maybe I was given a placebo?
5Patient Review
6/1/2016
Itraconazole for A Fungal Infection - Aspergillosis
I was put on this medication after extensive testing and consultation with three different doctors. Finally, a lung specialist diagnosed me with pneumonia. I've only been on the drug for three weeks, but it has already cost me $16,600 in hospital bills.
5Patient Review
1/22/2022
Itraconazole for Fungal Infection of Toenails
This treatment is excellent.
4.7Patient Review
11/3/2012
Itraconazole for Yeast Infection of Vagina and Vulva
I was diagnosed with histoplasmosis in October 2009 and put on Sporanox. Unfortunately, this led to a rapid decline in my liver function. I strongly recommend that you get your liver checked regularly if you are taking this medication.
4.7Patient Review
5/31/2014
Itraconazole for Ringworm of Groin Area
I was very alarmed when I found a bald spot on my head, especially because there were more spots by the following weekend. In addition to that, I experienced scalp itchiness and numbness in my limbs. After doing some research, I discovered that this medicine shouldn't be taken with simvastin; now that I've stopped taking it, the side effects are subsiding but they're still pretty bad. Does anyone know how long it takes for this medicine to leave your system?
4.3Patient Review
1/28/2020
Itraconazole for Fungal Infection of Toenails
I just completed a 3-month course of this medication for toenail fungus. I didn't notice any side effects and my new nail is coming through fine, although there is still some discoloration at the top. The medication definitely stopped it from spreading and seems to be working. Only time will tell if the fungus comes back on the fresh nail.
4.3Patient Review
1/30/2012
Itraconazole for Fungal Infection of Toenails
4Patient Review
3/30/2013
Itraconazole for Yeast Infection of Vagina and Vulva
I've been dealing with this toenail infection for over five years now, and I've tried Lamasil three times. The first time I used it, I did so for over a year straight with very little effect. However, my recent pulse treatment--which consists of taking the medication for one week out of every month, twice daily--has cleared up all but one big toe. There were no side effects that I noticed; though, it's worth mentioning that I already have a sensitive stomach due to minor lactose intolerance.
3.7Patient Review
4/13/2014
Itraconazole for Fungal Infection of Fingernails - Onychomycosis
I've only been taking this for a day and I feel SO much better. This is the quickest acting yeast medication I've ever taken. I usually have to take oral medications because I get really bad infections of non-albicans species, but this seems to be more effective than Diflucan with less indigestion. Taking it twice a day for a week isn't too bad, obviously once a day for fewer days would be ideal but this stuff really helps so I don't mind!
3.7Patient Review
11/12/2010
Itraconazole for Fungal Infection of Toenails
3.3Patient Review
5/4/2012
Itraconazole for Infection caused by Coccidioides Fungus
While this did eventually help with my muscle cramps, the process was slow and uncomfortable.
3Patient Review
1/7/2011
Itraconazole for Type of Infection caused by Histoplasmosis Fungus
2.3Patient Review
3/11/2013
Itraconazole for Yeast Infection of Vagina and Vulva
I lost 17 pounds from all the nausea this treatment caused me.
2.3Patient Review
4/24/2018
Itraconazole for Chronic Fungal Infection of Skin
This drug effectively addressed my toenail fungus issue. Better than Lamisil, and now I don't have to be embarrassed anymore.
1.7Patient Review
10/17/2021
Itraconazole for Fungal Infection of Toenails
The only good thing about this treatment is that it smells pretty bad. I've been using it for almost two years now, and it doesn't seem to be doing anything. If anything, it seems like it's made my toenail infection worse.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about itraconazole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of taking itraconazole?

"You may experience nausea or vomiting, diarrhea, headache, stomach upset, or dizziness. If you experience any of these effects for an extended period of time, or if they worsen, contact your doctor or pharmacist."

Answered by AI

Is itraconazole a steroid?

"Itraconazole is used to treat fungal infections of the toenails and fingernails.

Itraconazole does not contain steroids. It is an antifungal medication that belongs to the triazole class of drugs. It is highly effective against common fungal infections. Itraconazole is used to treat fungal infections of the toenails and fingernails."

Answered by AI

How long can itraconazole be taken?

"Itraconazole oral solution is recommended to be taken on an empty stomach once or twice a day, for a duration of 1 to 4 weeks, or sometimes longer if needed. It is important to follow the directions on the prescription label carefully and to ask your doctor or pharmacist to explain any part of the instructions that you do not understand."

Answered by AI

What is itraconazole used for?

"This medication is used to treat fungal infections such as aspergillosis (fungal infection in the lungs), blastomycosis (Gilchrist's disease), or histoplasmosis (Darling's disease). It is also used to treat onychomycosis (fungal infection in the fingernails or toenails)."

Answered by AI

Clinical Trials for Itraconazole

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Itraconazole clinical trials? We made a collection of clinical trials featuring Itraconazole, we think they might fit your search criteria.Go to Trials
Have you considered Itraconazole clinical trials? We made a collection of clinical trials featuring Itraconazole, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Itraconazole clinical trials? We made a collection of clinical trials featuring Itraconazole, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security